6 results match your criteria: "Rheumatology Hospital "Madonna Dello Scoglio[Affiliation]"

Objectives: To better define the spectrum of new-onset post-COVID-19 and post-COVID-19 vaccine inflammatory rheumatic diseases (IRD) from a large multicentric observational study.

Methods: Consecutive cases of IRD encountered during a 12-month period and satisfying one of the following inclusion criteria: (a) onset of the rheumatic manifestations within 4 weeks from SARS-CoV-2 infection or (b) onset of the rheumatic manifestations within 4 weeks from the administration of one of the COVID-19 vaccines ws recruited.

Results: The final analysis cohort comprised 267 patients, of which 122 (45.

View Article and Find Full Text PDF
Article Synopsis
  • Adalimumab is a treatment for noninfectious uveitis, but a 32-year-old woman experienced spondyloarthritis symptoms while on it.* -
  • After confirming her spondyloarthritis diagnosis, she switched to secukinumab for treatment and stopped adalimumab.* -
  • The switch led to significant symptom relief and decreased inflammation, showing secukinumab's effectiveness in treating joint pain related to uveitis without causing uveitis relapses.*
View Article and Find Full Text PDF